“Both VX-150 and VX-128 represent an innovative new approach to the treatment of pain, and we are encouraged to now have positive proof-of-concept data from two studies of VX-150 that demonstrate for ...
- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...
Vertex Pharmaceuticals Incorporated data readout from a phase 3 program, using VX-548 for the treatment of patients with acute pain, could be released by the 1st half of 2024. Proof of concept, using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback